|
10086
|
YF-Vax
|
Yellow fever
|
Hemorrhagic
|
Yellow fever virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Sanofi Pasteur
|
NA
|
France
|
9 months and above
|
Single dose
|
Subcutaneous
|
NA
|
17D-204 strain of yellow fever virus
|
Culturing 17D-204 strain of yellow fever virus in living avian leukosis virus-free (ALV-free) chicken embryos
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.fda.gov/media/76015/download
|
https://www.fda.gov/media/76015/download
|
|
10209
|
XRX-001 Inactivated yellow fever vaccine
|
Yellow fever
|
Hemorrhagic
|
Yellow fever virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 1
|
GE Healthcare
|
2016
|
USA
|
18 - 49 years
|
NA
|
NA
|
Aluminum (alum)
|
Yellow fever virus
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT00995865
|
https://clinicaltrials.gov/ct2/show/NCT00995865?recrs=abde&cond=yellow+fever&phase=0123&draw=2&rank=4
|
NA
|
|
10363
|
STAMARiL
|
Yellow fever
|
Hemorrhagic
|
Yellow fever virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 3
|
Sanofi Pasteur
|
NA
|
France
|
10 months
|
Single dose
|
Subcutaneous
|
NA
|
17D-204 strain of yellow fever virus
|
Produced in specified pathogen-free chick embryos
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.sanofipasteur.co.uk/-/media/ems/conditions/vaccines/brands/oneportal-ie/pdf/105_stamaril_mah_address_update_12_2017_uk.pdf
|
NA
|